CLLS
- Cellectis S.A.
()
Overview
Company Summary
Cellectis S.A. (CLLS) is a multinational biotechnology company that primarily focuses on developing and commercializing innovative cellular engineering technologies. The company specializes in the field of gene editing, specifically using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology.
Cellectis aims to address critical challenges in the healthcare industry by developing personalized immunotherapies for the treatment of cancer. The company's proprietary gene editing platform, known as TALEN�, allows precise modifications to be made in the genetic code of living cells. This technology enables Cellectis to engineer and control immune cells, primarily T-cells, to target and eliminate cancer cells.
One of the key applications of Cellectis' technologies is the development of chimeric antigen receptor T-cell (CAR-T) therapies. CAR-T therapies involve genetically modifying a patient's own T-cells to express chimeric antigen receptors, enabling the immune system to recognize and attack cancer cells.
Cellectis has a pipeline of CAR-T products in various stages of development, targeting different types of cancer. Their lead product, UCART19, focuses on the treatment of B-cell acute lymphoblastic leukemia (B-ALL) and currently is in advanced stages of clinical development. Additionally, the company is actively exploring applications of gene editing technology in other areas, including immuno-oncology, genetic diseases, and regenerative medicine.
Overall, Cellectis S.A. is dedicated to leveraging cutting-edge gene editing technologies to revolutionize cancer treatment and provide potentially curative therapies for patients worldwide.